CHRM4 (Muscarinic Acetylcholine Receptor M4) Drug Discovery Landscape & Assay Solutions
- By admin
- 08 Aug 2026
- Comments
Subtitle: Market Intelligence on M4-Selective PAMs, Clinical Progress, and High-Purity Reagents for CNS Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRM4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Cell Line System | CHRM4 Lentivirus Premade Particles. Full-length GPCR for stable cell line construction, preserving native conformation and glycosylation. Titers >10^8 TU/mL. | View CHRM4 Products |
| Antigen | CHRM4 ECD (N-Terminal Domain) Protein. High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed. Sequence Verified. | View CHRM4 Products |
| Reference Control | Anti-CHRM4 Monoclonal Antibody. Sequence Verified research grade for binding assay validation. | View CHRM4 Products |
| Validator | CHRM4 siRNA Set. For knockdown verification and specificity controls. | View CHRM4 Products |
| Related Target (Selectivity) | CHRM1 (Muscarinic M1). Counter-screening for CNS-targeting drugs to ensure M4 selectivity. | View CHRM1 Products |
| Related Target (Selectivity) | CHRM2 (Muscarinic M2). Peripheral/CNS selectivity profiling. | View CHRM2 Products |
| Related Target (Selectivity) | CHRM3 (Muscarinic M3). Counter-screening target to avoid peripheral autonomic side effects. | View CHRM3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation & Signaling | Lentivirus-mediated stable expression in HEK293 cells; Native glycosylation; Suitable for Calcium Flux, cAMP, and β-arrestin assays. |
| Muscarinic Receptor Selectivity (M1/M2/M3/M5) | Ortholog panel available: Human/Mouse/Cyno CHRM4 plus CHRM1/CHRM2/CHRM3/CHRM5 proteins for strict counter-screening. |
| Species Cross-Reactivity (Preclinical) | Human, Cynomolgus, and Mouse CHRM4 sequences verified by mass spec; >95% purity. |
| Assay Specificity Controls | CHRM4-specific siRNA included for target engagement confirmation. |
Live CHRM4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHRM4 therapeutics is intensifying, with major players shifting focus from broad muscarinic agonists to highly selective allosteric modulators (PAMs). As first-generation therapies targeting schizophrenia and Alzheimer's disease psychosis reach advanced clinical stages, the next wave of R&D is targeting improved subtype selectivity and minimizing peripheral adverse effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAMs) | Karuna Therapeutics, Cerevel Therapeutics | Schizophrenia, Psychosis | Cell-based Functional Assay (Need Lentivirus for stable cell lines) |
| Biologics/Antibodies | Emerging Biotech | Neurological Disorders | Subtype Selectivity Assay (Need Homolog Panel Proteins) |
| Gene Therapy | Academic/Early Biotech | Refractory CNS Diseases | Expression Validation (Need sequence-verified ORFs) |
Key Therapeutic Indications and Pipeline Insights
CHRM4 is a high-value CNS target, primarily pursued for schizophrenia, Alzheimer's disease psychosis, and Parkinson's disease. The leading modality is small molecule positive allosteric modulators (PAMs), which offer improved subtype selectivity over orthosteric agonists. Major players include Karuna Therapeutics (KarXT, M1/M4 agonist) and Cerevel Therapeutics (emraclidine, M4 PAM). The field is rapidly consolidating, with acquisitions by BMS and AbbVie underscoring the commercial potential.
Assay Strategy and Differentiation
Achieving best-in-class CHRM4 drugs requires:
- Subtype Selectivity: Strict counter-screening against M1, M2, M3, and M5 to avoid peripheral side effects.
- Allosteric Modulation: PAM activity enhances endogenous acetylcholine signaling without direct activation.
- BBB Penetration: Essential for CNS efficacy.
Recommended assays include cell-based functional assays (cAMP inhibition, calcium flux via chimeric G proteins) using stable cell lines, and a comprehensive counter-screening panel. TarMart provides lentivirus particles for rapid cell line generation and full family ORF clones for selectivity profiling.